An international team of researchers, including Dr Eamon McCarron, Consultant and Clinical Lead in Adult Inherited Metabolic Disorders at Sheffield Teaching Hospitals NHS Foundation Trust, has developed a groundbreaking new framework to classify more than 100 rare genetic disorders linked to lysosomal disease.
The updated classification system is designed to improve the diagnosis of inherited lysosomal disorders, enhance the interpretation of genetic test results and help identify groups of patients who could benefit from shared treatments and clinical trials.
Lysosomes are essential structures within cells responsible for breaking down and recycling cellular waste. Historically, lysosomal disorders have been viewed primarily as diseases caused by enzyme deficiencies that lead to the build-up of harmful substances within cells. However, advances in understanding lysosomal biology have revealed a much broader spectrum of disease mechanisms.
Although individual lysosomal disorders are rare, collectively they affect between one in every 4,000 and 10,000 live births. Early diagnosis is particularly important as timely intervention can prevent irreversible damage and significantly improve patient outcomes.
The newly developed framework brings together 108 inherited lysosomal disorders and reflects the latest scientific understanding of lysosomal function and disease pathways. Researchers believe it will provide clinicians with a clearer picture of how these conditions are interconnected, paving the way for more personalised approaches to diagnosis and treatment.
Dr Eamon McCarron, Consultant and Clinical Lead in Adult Inherited Metabolic Disorders at Sheffield Teaching Hospitals NHS Foundation Trust, said:
“Lysosomal disorders are a group of rare but collectively common diseases, and their effects can be debilitating, impacting severely on quality of life and function, and, in some cases, are life-limiting and life-shortening. By bringing together 108 inherited disorders within a framework based on modern lysosomal biology, we hope to provide a clearer way of understanding how these diseases relate to one another.
“Crucially, this could support more precise, timely diagnosis, allow doctors to detect life-threatening, treatable lysosomal conditions before symptoms start and help researchers identify shared disease mechanisms that could become targets for new treatments. For ultra-rare conditions, grouping patients by shared biology could also help inform the design of future clinical trials. Genetic testing is also playing an increasingly important role in routine care, and it is hoped this definition will support the ambitions of the Ten-Year Health Plan to make a difference to the health of the nation through next generation sequencing technologies and expanding newborn screening programmes.”
The Sheffield Adult Inherited Metabolic Disorders Service is one of seven specialist adult inherited metabolic disorder services commissioned by NHS England. The service provides expert care and support for patients living with rare inherited metabolic conditions across the region.
The study was co-led by Dr Karolina Stepien, Consultant in Adult Inherited Metabolic Diseases at Salford Royal Hospital, and involved leading researchers and clinicians from across the UK and internationally. Key collaborators included the University of Sheffield, University of Oxford, University College London, University of Manchester, University Children’s Hospital Zürich, Leiden University and the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the US National Institutes of Health.
Researchers believe the framework could play an important role in shaping future newborn screening programmes, accelerating the adoption of genomic medicine and supporting the development of targeted therapies for some of the world's rarest diseases.
Image credit: iStock
